I think they have a very solid product, present in 30 countries and 8 jurisdictions. I saw this kind of performance with Novo Nordisk and I think OncoSil has a similar profile. Innovation + strong management/commercial strategy does it for me. It's going to become the new pancreatic cancer medication used everywhere. I see the current market consolidation phase as a buying strategy.
Ann: Appendix 4D and Half Year Accounts, page-22
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.58M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $99.72K | 11.05M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 6025000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 2885714 | 3 |
View Market Depth
| Last trade - 13.12pm 22/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |